COMPANY PROFILE // THE 014 REPORT
Cadrenal Therapeutics, Inc.
CVKD (Nasdaq)
Assembled from 2 government sources in 3.7 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber6 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-09-29: a pattern of leadership change.
✓ SEC filings✗ LEI✗ SAM registration✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no state registration, no website, no lobbying registration on record.
Cadrenal Therapeutics, Inc. is an SEC-registered operating company in pharmaceutical preparations, incorporated in DE, based in Ponte Vedra, FL; listed as CVKD (Nasdaq).[source] It has filed 74 documents with the SEC in the last 12 months; the latest is a SCHEDULE 13G, filed 2026-11-17.[source] Its largest institutional holders on 13F filings are VANGUARD CAPITAL MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, VANGUARD FIDUCIARY TRUST CO (as of 2026-06-30).[source] Seraphix flags 1 item from these records: 6 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-09-29.[source]
- red0
- amber1
- info0
- VANGUARD CAPITAL MANAGEMENT LLC$167K
- GEODE CAPITAL MANAGEMENT, LLC$64K
- VANGUARD FIDUCIARY TRUST CO$28K
- Tower Research Capital LLC (TRC)$4K
- UBS Group AG$4K
- Grove Bank & Trust$3K
- Clearstead Advisors, LLC$2K
- Quest 10 Wealth Builders, Inc.$1K
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Pham Quang X · CEO and Chairman (Director,Officer,10% owner) · latest Form 4 2025-10-28 · filing · LinkedIn search
- Szot Matthew K · Chief Financial Officer (Officer) · latest Form 4 2025-12-31 · filing · LinkedIn search
- Golden Lee Scott · Director · latest Form 4 2025-12-03 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- BLANK ROME LLP · Exhibit 5.1 legal opinion, S-8 filed 2026-10-08
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001937993 | source |
| EIN | 88-0860746 | source |
| Business address (SEC) | 822 A1A NORTH, PONTE VEDRA, FL, 32082 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 131 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 176 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
ADDRESS · ZIP CODE
Location context
At the same address (2)
- STARLIGHT PATH COMMUNITY CARE INC · IRS-registered organization
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- INVO Fertility, Inc. · Szot Matthew K
- SenesTech, Inc. · Szot Matthew K
- PTC THERAPEUTICS, INC. · Golden Lee Scott
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-16 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-10-08 filing S-8 · SEC EDGAR
- 2026-10-07 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-09-29 officer change 8-K items 5.02,5.07,9.01 · SEC EDGAR
- 2026-09-03 filing S-8 · SEC EDGAR
- 2026-08-31 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-08-13 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-13 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-08-03 filing DEFA14A · SEC EDGAR
- 2026-08-03 filing ARS · SEC EDGAR
- 2026-08-03 filing Proxy statement · SEC EDGAR
- 2026-07-23 filing PRE 14A · SEC EDGAR
- 2026-07-21 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-07-20 filing EFFECT · SEC EDGAR
- 2026-07-20 filing 424B3 · SEC EDGAR
- 2026-07-17 officer change 8-K items 5.02,9.01 · SEC EDGAR
- 2026-07-15 filing D · SEC EDGAR
- 2026-07-13 filing S-3 · SEC EDGAR
- 2026-07-10 officer change 8-K items 5.02,9.01 · SEC EDGAR
- 2026-07-01 filing 8-K items 1.01,3.02,8.01,9.01 · SEC EDGAR
- 2026-06-29 officer change 8-K items 5.02,9.01 · SEC EDGAR
- 2026-06-18 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-06-15 filing 144 · SEC EDGAR
- 2026-06-03 officer change 8-K items 5.02,9.01 · SEC EDGAR
- 2026-05-11 filing 144 · SEC EDGAR
- 2026-05-07 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-05-07 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-04-30 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-04-29 filing EFFECT · SEC EDGAR
- 2026-04-29 filing 424B3 · SEC EDGAR
170 earlier entries
- 2026-04-27 filing CORRESP
- 2026-04-27 filing UPLOAD
- 2026-04-21 filing S-3
- 2026-04-06 filing D
- 2026-04-01 filing 8-K items 1.01,3.02,3.03,9.01
- 2026-04-01 filing 424B5
- 2026-03-31 filing Annual report (10-K)
- 2026-03-31 filing 8-K items 2.02,9.01
- 2026-03-12 filing 8-K items 7.01,8.01,9.01
- 2026-02-24 filing 8-K items 8.01,9.01
- 2026-01-02 filing 424B3
- 2025-12-31 filing EFFECT
- 2025-12-31 filing D
- 2025-12-31 filing UPLOAD
- 2025-12-30 filing CORRESP
- 2025-12-29 filing 144
- 2025-12-29 filing Registration (S-1)
- 2025-12-23 filing 8-K items 8.01,9.01
- 2025-12-23 filing 424B5
- 2025-12-16 filing 8-K items 1.01,3.02,9.01
- 2025-12-16 filing 424B5
- 2025-12-16 filing 424B5
- 2025-12-11 filing 8-K items 1.01,7.01,8.01,9.01
- 2025-12-03 insider First Form 3/4/5 on record for Golden Lee Scott (Director)
- 2025-12-01 officer change 8-K items 5.02,8.01,9.01
- 2025-11-18 filing 8-K items 8.01,9.01
- 2025-11-18 filing 424B5
- 2025-11-10 filing 8-K items 2.02,9.01
- 2025-11-10 filing Quarterly report (10-Q)
- 2025-10-27 filing 144
- 2025-10-27 filing 144
- 2025-10-24 filing 144
- 2025-10-24 filing 144
- 2025-10-14 filing 144
- 2025-10-14 filing 144
- 2025-10-09 filing 144
- 2025-10-09 filing 144
- 2025-10-06 filing 144
- 2025-10-02 filing 144
- 2025-10-01 filing 144
- 2025-10-01 filing 144
- 2025-09-29 filing 144
- 2025-09-29 filing 144
- 2025-09-29 filing 144/A
- 2025-09-25 filing 144
- 2025-09-25 filing 144
- 2025-09-24 filing 144
- 2025-09-24 filing 144
- 2025-09-24 filing 8-K items 5.07
- 2025-09-15 filing 8-K items 1.01,7.01,8.01,9.01
- 2025-08-29 insider First Form 3/4/5 on record for Pham Quang X (CEO and Chairman)
- 2025-08-29 insider First Form 3/4/5 on record for Szot Matthew K (Chief Financial Officer)
- 2025-08-28 filing 144
- 2025-08-28 filing 144
- 2025-08-27 filing 144
- 2025-08-27 filing 144/A
- 2025-08-27 filing 144
- 2025-08-11 filing 8-K items 2.02,9.01
- 2025-08-11 filing Quarterly report (10-Q)
- 2025-08-05 filing 8-K items 8.01,9.01
- 2025-07-31 filing ARS
- 2025-07-31 filing DEFA14A
- 2025-07-31 filing Proxy statement
- 2025-07-18 officer change 8-K items 5.02,5.08,8.01,9.01
- 2025-05-08 filing 8-K items 2.02,9.01
- 2025-05-08 filing Quarterly report (10-Q)
- 2025-04-17 filing 8-K items 8.01,9.01
- 2025-04-17 filing 424B5
- 2025-03-13 filing 8-K items 2.02,9.01
- 2025-03-13 filing Annual report (10-K)
- 2025-03-04 filing 8-K items 1.01,8.01,9.01
- 2025-02-07 officer change 8-K items 5.02,8.01,9.01
- 2025-02-03 filing S-8
- 2025-01-29 filing SCHEDULE 13D
- 2024-12-23 filing S-8
- 2024-12-20 filing 424B5
- 2024-11-25 filing 424B3
- 2024-11-22 filing EFFECT
- 2024-11-21 filing CORRESP
- 2024-11-20 filing UPLOAD
- 2024-11-14 filing S-3
- 2024-11-14 filing D
- 2024-11-07 filing Quarterly report (10-Q)
- 2024-11-07 filing 8-K items 2.02,9.01
- 2024-11-04 filing 8-K items 1.01,3.02,3.03,8.01,9.01
- 2024-11-04 filing 424B5
- 2024-10-24 filing 8-K items 7.01,8.01,9.01
- 2024-09-25 filing 8-K items 7.01,8.01,9.01
- 2024-09-05 filing 8-K items 3.01,9.01
- 2024-08-20 filing 8-K items 3.03,5.03,8.01,9.01
- 2024-08-16 filing 8-K items 3.03,5.03,8.01,9.01
- 2024-08-08 filing 8-K items 2.02,9.01
- 2024-08-07 filing Quarterly report (10-Q)
- 2024-08-06 filing 8-K items 7.01,8.01,9.01
- 2024-07-31 officer change 8-K items 5.02,5.07,9.01
- 2024-06-12 filing DEFA14A
- 2024-06-11 filing ARS
- 2024-06-11 filing Proxy statement
- 2024-05-29 filing PRE 14A
- 2024-05-09 filing Quarterly report (10-Q)
- 2024-05-09 filing 8-K items 5.08,8.01,9.01
- 2024-04-09 filing 8-K items 7.01,8.01,9.01
- 2024-04-02 filing EFFECT
- 2024-04-02 filing POS AM
- 2024-03-20 filing EFFECT
- 2024-03-18 filing CORRESP
- 2024-03-15 filing UPLOAD
- 2024-03-12 filing S-8
- 2024-03-12 filing S-3
- 2024-03-12 filing 8-K items 1.01,9.01
- 2024-03-11 filing 8-K items 2.02,9.01
- 2024-03-11 filing Annual report (10-K)
- 2024-03-05 filing 8-K items 3.01,9.01
- 2024-02-15 filing 8-K/A items 3.01,9.01
- 2024-02-12 officer change 8-K items 5.02,8.01,9.01
- 2023-11-09 filing 8-K items 2.02,9.01
- 2023-11-09 filing Quarterly report (10-Q)
- 2023-10-23 filing 8-K items 5.07,9.01
- 2023-09-08 filing 8-K items 3.01,9.01
- 2023-08-31 filing DEFA14A
- 2023-08-31 filing DEFA14A
- 2023-08-28 filing ARS
- 2023-08-28 filing Proxy statement
- 2023-08-18 filing 8-K items 7.01,9.01
- 2023-08-16 filing 8-K items 5.08,8.01,9.01
- 2023-08-16 filing 424B3
- 2023-08-10 filing 8-K items 2.02,9.01
- 2023-08-10 filing Quarterly report (10-Q)
- 2023-08-01 filing 424B3
- 2023-07-28 filing EFFECT
- 2023-07-26 filing CORRESP
- 2023-07-26 filing UPLOAD
- 2023-07-24 officer change 8-K items 5.02,8.01,9.01
- 2023-07-24 filing Registration (S-1)
- 2023-07-18 filing D
- 2023-07-14 filing 8-K items 1.01,3.02,8.01,9.01
- 2023-05-26 officer change 8-K items 5.02,9.01
- 2023-05-10 filing Quarterly report (10-Q)
- 2023-05-10 filing 8-K items 2.02,9.01
- 2023-03-31 filing 3/A
- 2023-03-30 filing Annual report (10-K)
- 2023-03-27 filing 8-K items 7.01,9.01
- 2023-01-25 officer change 8-K items 1.01,3.02,5.02,8.01,9.01
- 2023-01-24 filing S-8
- 2023-01-23 filing 424B4
- 2023-01-23 filing 424B4
- 2023-01-20 filing SEC STAFF LETTER
- 2023-01-20 filing CERT
- 2023-01-19 filing EFFECT
- 2023-01-17 filing 8-A12B
- 2023-01-17 filing CORRESP
- 2023-01-17 filing CORRESP
- 2023-01-17 filing S-1/A
- 2022-12-28 filing S-1/A
- 2022-12-08 filing CORRESP
- 2022-12-08 filing S-1/A
- 2022-12-08 filing D
- 2022-12-08 filing UPLOAD
- 2022-12-06 filing S-1/A
- 2022-10-17 filing S-1/A
- 2022-10-17 filing CORRESP
- 2022-10-13 filing UPLOAD
- 2022-10-12 filing SEC STAFF LETTER
- 2022-10-11 filing S-1/A
- 2022-09-22 filing CORRESP
- 2022-09-22 filing Registration (S-1)
- 2022-09-02 filing DRSLTR
- 2022-09-02 filing DRS/A
- 2022-08-30 filing UPLOAD
- 2022-08-23 filing DRSLTR
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-16 (within 7 days) 10-Q filed (QUARTERLY REPORT)
- 2026-10-08 (older) S-8 filed (REGISTRATION STATEMENT)
- 2026-10-07 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-09-29 (older) 8-K filed: Item 5.02 officer or director change; Item 5.07 shareholder vote; Item 9.01 exhibits
- 2026-09-03 (older) S-8 filed (REGISTRATION STATEMENT)
- 2026-08-31 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-08-13 (older) 10-Q filed (QUARTERLY REPORT)
- 2026-08-13 (older) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-20; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:CVKD The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
0 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1937993 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | CVKD / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 880860746 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001937993 | SEC EDGAR / IRS |
| CUSIP | 127636207 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001937993 | SEC EDGAR |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Net income (loss) (fiscal year ended 2025-12-31) | -$13,237,362 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-20 10:03 UTC | Report an error |
| Total assets (at 2025-12-31) | $4,326,708 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-20 10:03 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $2,738,726 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-20 10:03 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $4,007,789 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-20 10:03 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-20 10:03 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-20 10:03 UTC | Report an error |
| State of incorporation | DE | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-20 10:03 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-20 10:03 UTC | Report an error |
| Business address | 822 A1A NORTH, SUITE 306, PONTE VEDRA, FL, 32082 | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-20 10:03 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-20 10:03 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$12,601,666 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-20 10:03 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $5,104 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-20 10:03 UTC | Report an error |
| Form D total offering amount (D filed 2026-07-15) | $8,843,849 | 2026-07-15 | D | as filed | 2026-11-20 10:03 UTC | Report an error |
| Form D total amount sold (D filed 2026-07-15) | $8,843,849 | 2026-07-15 | D | as filed | 2026-11-20 10:03 UTC | Report an error |
| Form D industry group | Biotechnology | 2026-07-15 | D | as filed | 2026-11-20 10:03 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2026-07-15 | D | as filed | 2026-11-20 10:03 UTC | Report an error |
| Form D date of first sale | 2026-06-30 | 2026-07-15 | D | as filed | 2026-11-20 10:03 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-16 · accession 0001213900-26-120837
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Net income (loss) | -$1,246,871 | 3 months ended 2026-09-30 | 10-Q | 2026-11-16 | 0001213900-26-120837 | 2026-11-20 10:03 UTC | Report an error |
| Cash and cash equivalents | $3,056,086 | at 2026-09-30 | 10-Q | 2026-11-16 | 0001213900-26-120837 | 2026-11-20 10:03 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-16 Filing 10-Q filed (QUARTERLY REPORT)
- 2026-10-08 Filing S-8 filed (REGISTRATION STATEMENT)
- 2026-10-07 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-09-29 Filing 8-K filed: Item 5.02 officer or director change; Item 5.07 shareholder vote; Item 9.01 exhibits
- 2026-09-03 Filing S-8 filed (REGISTRATION STATEMENT)
- 2026-08-31 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-08-13 Filing 10-Q filed (QUARTERLY REPORT)
- 2026-08-13 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-08-03 Filing DEFA14A filed (DEFINITIVE ADDITIONAL MATERIALS)
- 2026-08-03 Filing ARS filed (FORM ARS)
- 2026-08-03 Filing DEF 14A filed (PROXY STATEMENT)
- 2026-07-23 Filing PRE 14A filed (PROXY STATEMENT)
- 2026-07-21 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-07-20 Filing EFFECT filed
- 2026-07-20 Filing 424B3 filed (PROSPECTUS)
- 2026-07-17 Filing 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-07-15 Filing D filed
- 2026-07-13 Filing S-3 filed (REGISTRATION STATEMENT)
- 2026-07-10 Filing 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-07-01 Filing 8-K filed: Item 1.01 material agreement; Item 3.02 unregistered equity sale; Item 8.01 other event; Item 9.01 exhibits
- 2026-06-29 Filing 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-06-18 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-06-03 Filing 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-05-07 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-05-07 Filing 10-Q filed (QUARTERLY REPORT)
8-K item text, as filed (excerpts)
- 2026-10-07 8-K Item 8.01, Other Events
On October 7, 2026, the Company issued a press release announcing that its Board of Directors has authorized the Company to initiate a formal strategic process to evaluate opportunities to maximize the value of the Company and its asset portfolio. Potential opportunities may include licensing or sale of individual assets, development and commercialization partnerships, portfolio transactions, business combinations, or other strategic transactions. The strategic review is at a preliminary stage, and the Company has not set a deadline or definitive timetable for the completion of the process. There can be no assurance that the strategic process will result in any transaction or other… the 8-K · retrieved 2026-11-20 10:03 UTC - 2026-09-29 8-K Item 5.02, Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Amendment to 2022 Successor Equity Incentive Plan On September 24, 2026, Cadrenal Therapeutics, Inc. (the “Company”), held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). At the 2026 Annual Meeting, the Company’s stockholders approved an amendment (the “Amendment No. 2”) to the Company’s 2022 Successor Equity Incentive Plan, as amended (the “2022 Plan”), to increase the number of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), that will be available for awards under the 2022 Plan by 323,542 shares to 1,000,000 shares. A… the 8-K · retrieved 2026-11-20 10:03 UTC - 2026-09-29 8-K Item 5.07, Submission of Matters to a Vote of Security Holders
On September 24, 2026, the Company held its 2026 Annual Meeting at which the Company’s stockholders voted on the following five (5) proposals and cast their votes as described below. These matters are described in detail in the Proxy Statement. As of July 27, 2026, the record date for the 2026 Annual Meeting, there were 3,567,592 shares of Common Stock outstanding and entitled to vote at the 2026 Annual Meeting. Present in person or by proxy at the 2026 Annual Meeting were 2,155,341 shares of Common Stock, which constituted a quorum. The final voting results for each item of business voted upon at the 2026 Annual Meeting, as described in the Proxy Statement, is set forth below. Proposal 1.… the 8-K · retrieved 2026-11-20 10:03 UTC - 2026-08-31 8-K Item 7.01, Regulation FD Disclosure
On August 31, 2026, Cadrenal Therapeutics, Inc. (the “Company”) issued a press release announcing positive feedback from a Type D Meeting with the U.S. Food and Drug Administration (“FDA”) held on July 28, 2026. During the meeting, the Company and the FDA aligned on key aspects of the protocol and Statistical Analysis Plan for a Phase 3 registrational study of CAD-1005, the Company’s first-in-class 12-lipoxygenase (“12-LOX”) inhibitor in development to treat heparin-induced thrombocytopenia (“HIT”). During the Type D meeting, the FDA agreed on an optimized definition of worsening HIT for the primary endpoint, based on progression of thrombotic events through Day 14 of treatment or hospital… the 8-K · retrieved 2026-11-20 10:03 UTC - 2026-08-31 8-K Item 8.01, Other Events
On August 31, 2026, the Company issued a press release announcing positive feedback from a Type D Meeting with the FDA held on July 28, 2026. During the meeting, the Company and the FDA aligned on key aspects of the protocol and Statistical Analysis Plan for a Phase 3 registrational study of CAD-1005, the Company’s first-in-class 12-LOX inhibitor in development to treat HIT. During the Type D meeting, the FDA agreed on an optimized definition of worsening HIT for the primary endpoint, based on progression of thrombotic events through Day 14 of treatment or hospital discharge. To ensure high-quality, reliable endpoint evaluation across clinical sites, the worsening component of the primary… the 8-K · retrieved 2026-11-20 10:03 UTC - 2026-08-13 8-K Item 2.02, Results of Operations and Financial
Condition. On August 13, 2026, Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for the quarter ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in… the 8-K · retrieved 2026-11-20 10:03 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | $167,458 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:03 UTC | Report an error |
| 2 | GEODE CAPITAL MANAGEMENT, LLC | $63,540 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:03 UTC | Report an error |
| 3 | VANGUARD FIDUCIARY TRUST CO | $27,759 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:03 UTC | Report an error |
| 4 | Tower Research Capital LLC (TRC) | $4,282 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:03 UTC | Report an error |
| 5 | UBS Group AG | $3,714 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:03 UTC | Report an error |
| 6 | Grove Bank & Trust | $3,340 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:03 UTC | Report an error |
| 7 | Clearstead Advisors, LLC | $2,171 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:03 UTC | Report an error |
| 8 | Quest 10 Wealth Builders, Inc. | $1,269 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:03 UTC | Report an error |
| 9 | OSAIC HOLDINGS, INC. | $1,002 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:03 UTC | Report an error |
| 10 | Rockefeller Capital Management L.P. | $501 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:03 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1937993.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001937993. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.